Precision oncology

From DNA sequence to treatment decision

SmartADN is an Algerian AI startup building a SaaS platform for precision oncology. It turns a patient's sequencing data into a clear, evidence-based clinical report.

What SmartADN does

  • Imports sequencing files (FASTQ, VCF, BAM, Sanger AB1, CSV) up to 2 GB, with automatic quality control
  • Prioritises each genetic variant with an AI pathogenicity score (a triage aid, not an ACMG classification)
  • Maps relevant variants to diseases using the MONDO ontology and the OncoTree cancer classification
  • Surfaces therapeutic options from CIViC, with their level of clinical evidence
  • Generates a structured PDF report ready to share with the oncologist

Who it is for

Molecular biology and genetics laboratories, oncology departments, cancer centres, private clinics and cancer genomics research teams, primarily in Algeria and French-speaking countries.

Security

All traffic is encrypted over HTTPS. Each organisation has an isolated workspace with role-based access (administrator, physician), and every access is recorded in an audit log.

Pricing

Pay-per-report at 15,000 DZD, or monthly plans: Standard at 350,000 DZD (30 reports) and Premium at 600,000 DZD (60 reports). Onboarding and training are included with subscriptions.

Decision support only

SmartADN is a clinical decision-support tool. All results must be reviewed and validated by a qualified healthcare professional.

Frequently asked questions

What is SmartADN?

SmartADN is an AI SaaS platform for precision oncology that turns sequencing data into a clinical report with prioritised variants, associated diseases and evidence-based therapeutic options.

Which file formats are supported?

FASTQ, VCF, BAM, AB1 (Sanger), CSV and raw pasted sequences, up to 2 GB per file.

How can I get a demo?

Email contact.smartadn@gmail.com and our team will organise a demonstration.

Donnez à vos oncologues des réponses, pas des fichiers.

Découvrez en 30 minutes comment SmartADN transforme un fichier de séquençage en rapport clinique exploitable.